| Application no. and date | 20712673.1 (espacenet) (Federated) (European Patent Register), 20200313 | | Patent/reg. no. and date | DK/EP 3937914, 20230809 | | Publication date | 20220119 | | Priority no. and date | GB 201903546, 20190315 | | EP pub. no. and date |
EP 3937914 20220119 | | Effective date | | | Applicant/owner | LDN Pharma Limited, 45 Gresham Street
London EC2V 7BG, GB | | Applicant ref. no. | | | Inventor | LIU, Wai, 45 Gresham Street
London EC2V 7BG, GB,
DALGLEISH, Angus, 45 Gresham Street
London EC2V 7BG, GB | | Representative | | | Opponent | | | IPC Class | A61K 31/05 (2006.01) , A61K 31/08 (2006.01) , A61K 31/192 (2006.01) , A61K 31/352 (2006.01) , A61K 31/485 (2006.01) , A61K 31/555 (2006.01) , A61K 31/7068 (2006.01) , A61K 45/06 (2006.01) , A61P 35/00 (2006.01) | | Title | CANCER TREATMENT COMPRISING NALTREXONE AND A CANNABINOID | | Int. application no. | GB2020050638 | | Int. publication no. | WO2020188255 | | Related patent (certificate) | | | Status | Enhedspatent registreret | | Pædiatrisk forlængelse | - | | Udløbsdato for pædiatrisk forlængelse | - |
|
